medRxiv · 2021 · 22 citations · 21 references
PharmacyInfectious DiseasesPharmacotherapyInfectious Disease PharmacotherapyMolecular VirologyVirologyAntiretroviral TherapyAntiviral PharmacologyAntiviral PharmacotherapyAntiviral TherapyTreatmentAntiviral TherapeuticsDose ResponseIn Vivo StudiesIvermectin TreatmentParallel Study DesignsSars-cov-2 Antiviral TherapyViral Infection TreatmentViral Replication Control
ABSTRACT Introduction In vitro studies have shown the efficacy of Ivermectin (IV) to inhibit the SARS - CoV-2 viral replication, but questions remained as to In-vivo applications. We set out to explore the efficacy and safety of Ivermectin in persons infected with COVID19. Methods We conducted a translational proof of concept (PoC) randomized, double blind placebo controlled, dose response, parallel group study of IV efficacy in RT - PCR proven COVID 19 positive patients. 62 patients were randomized to 3 treatment groups. (A) IV 6mg regime, (B)IV 12 mg regime (given Q84hrs for 2weeks) (C, control) Lopinavir/Ritonavir. All groups plus standard of Care. Results The Days to COVID negativity [DTN] was significantly and dose dependently reduced by IV (p = 0.0066). The DTN for Control were, = 9.1+/−5.2, for A 6.0 +/− 2.9, and for B 4.6 +/−3.2. 2 Way repeated measures ANOVA of ranked COVID 19 + / − scores at 0, 84, 168, 232 hours showed a significant IV treatment effect (p=0.035) and time effect (p <0.0001). IV also tended to increase SPO2 % compared to controls, p = 0.073, 95% CI - 0.39 to 2.59 and increased platelet count compared to C (p = 0.037) 95%CI 5.55 - 162.55 × 10 3 /ml. The platelet count increase was inversely correlated to DTN (r = −0.52, p = 0.005). No SAE was reported. Conclusions 12 mg IV regime may have superior efficacy. IV should be considered for use in clinical management of SARS-Cov-2, and may find applications in community prophylaxis in high-risk areas.
21
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang, Yeming Wang, Xingwang Li et al. · The Lancet · 2020 · 51.8K citations · Full text
WHO Declares COVID-19 a Pandemic.
Domenico Cucinotta, Maurizio Vanelli · PubMed · 2020 · 7.8K citations · Full text
Public Health, Infectious Disease Control, Infectious Diseases +17
Persistent Symptoms in Patients After Acute COVID-19
Angelo Carfì, Roberto Bernabei, Francesco Landi · JAMA · 2020 · 4.8K citations · Full text
Veterinary Medicine, Infectious Diseases, Internal Medicine +9
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
Leon Caly, Julian Druce, Mike Catton et al. · Antiviral Research · 2020 · 2.3K citations · Full text